Brainstorm Cell Therapuetics, founded by CEO Chaim Lebovits and Co-CEO Dr. Stacy Lindborg, has developed a targeted, innovative, proprietary and validated autologous cellular technology platform (NurOwn®) for the treatment of neurodegenerative diseases. . BrainStorm is focused on developing clinical-stage autologous cellular therapy as a potentially transformative approach to treating neurodegenerative diseases. BrainStorm has developed a targeted, innovative, proprietary and validated autologous cellular technology platform (NurOwn®) for the treatment of neurodegenerative diseases. Brainstorm’s autologous MSC-NTF cellular therapy for Parkinson’s Disease (PD) is in preclinical trials.
×
Brainstorm Cell Therapeutics � NurOwn® for Parkinson's
© 2021 - Lifespan Extension Advocacy Foundation - LIFESPAN2023
The opinions expressed in interviews or commentary in articles appearing on this site are those of the subject or subjects and do not necessarily reflect the views of LEAF/Lifespan.io, its directors, officers or employees.
Powered by MMD